~~<i id='03363AF5D7'><strike id='03363AF5D7'><tt id='03363AF5D7'><pre id='03363AF5D7'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-10-01 01:54:19 Page View：1936

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Questions and answers about ramping up H5N1 bird flu vaccine
Next article： Peter Hotez and the public health issue of online harassment

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Questions and answers about ramping up H5N1 bird flu vaccine

ChristineKao/STATIftheH5N1birdfluviruseveracquirestheabilitytotransmiteasilytoandamongpeople—keepyou

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Humana CEO Bruce Broussard to step down in 2024

HumanaCEOBruceBroussardJasonDeCrow/APBruceBroussard,CEOofhealthinsurancegiantHumana,willstepdownnext